Tuesday, November 2, 2021 Daily Archives

Efficient and Scalable GMP Manufacture of AAV and LV with TransIT-VirusGEN® Reagent and Enhancers

by

This webcast features: Leisha Kopp, Applications Scientist, Mirus Bio Recombinant adenoassociated virus (AAV) and lentivirus (LV) are essential components of many gene and cell therapies designed to treat and potentially cure a vast array of acquired and heritable diseases. Thus, the need for large-scale manufacture of safe and effective viral vectors for the development of biotherapeutics has never been greater. In this webinar, we will examine critical optimization strategies that lead to simplified, defined workflows and enable higher AAV and…

November 2, 2021

Climate crisis: Big Pharma lays out its green credentials

by

As global leaders assemble at the COP26 meeting in Glasgow, we take a look at how Big Pharma is addressing environmental governance and how the top firms perform against their peers. Another quarter down, and another bout of pharma firms describe their financial successes and woes. But a number of companies have described their efforts to look after the environment, perhaps spurred on by COP26, the UN Climate Change Conference taking place in Glasgow, UK this week. UK pharma giant…

November 2, 2021

Accelerating Discoveries for Viral Biology and Host Immunity with Advanced Cell Analysis Solutions

by

This whitepaper summaries recently published studies that incorporated the Incucyte® Live-Cell analysis platform and iQue® 3 Advanced High-Throughput Flow Cytometry. These state-of-the-art technologies were used to simplify workflows and provide rapid analysis solutions and enhanced throughput, aiding the discovery of new insights on the host-pathogen life cycle throughout the course of infection. Post-infection, these platforms were leveraged to monitor exposure, assess immune protection, and accelerate the development of anti-viral small molecules, neutralizing antibodies, and vaccines. The Incucyte® platform offers automated…

November 2, 2021